| Antibacterial Agents | p. 1 |
| Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Bacterial Infectious Diseases | p. 3 |
| Aminoglycosides | p. 21 |
| Aztreonam | p. 45 |
| Beta-lactam and Beta-lactamase Inhibitor Combinations (Amoxicillin/Clavulanic, Ampicillin/Sulbactam, Piperacillin/Tazobactam, Ticarcillin/Clavulanic) | p. 55 |
| Carbapenems (Biapenem, Ertapenem, Faropenem, Imipenem, Meropenem, Panipenem) | p. 71 |
| Cephalosporins | p. 89 |
| Chloramphenicol | p. 121 |
| Clindamycin | p. 131 |
| Daptomycin | p. 149 |
| Fosfomycin | p. 163 |
| Fusidic Acid | p. 171 |
| Glycopeptides (Dalbavancin, Oritavancin, Teicoplanin, Vancomycin) | p. 181 |
| Ketolides (Telithromycin, Cethromycin) | p. 201 |
| Linezolid and Other Oxazolidinones | p. 223 |
| Macrolides | p. 243 |
| Metronidazole | p. 281 |
| Mupirocin | p. 293 |
| Nitrofurantoin | p. 305 |
| Penicillins | p. 309 |
| Quinolones | p. 337 |
| Quinupristin/Dalfopristin | p. 367 |
| Rifamycins for Mycobacterial Infections | p. 383 |
| Rifamycins for Nonmycobacterial Infections | p. 403 |
| Sulfonamides | p. 455 |
| Tetracyclines and Analogues | p. 461 |
| Tigecycline | p. 477 |
| Trimethoprim and Trimethoprim-Sulfamethoxazole (Cotrimoxazole) | p. 485 |
| Antimycobacterial Agents | p. 501 |
| Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Mycobacterial Infections | p. 503 |
| Cycloserine | p. 517 |
| Ethambutol | p. 523 |
| Ethionamide | p. 533 |
| Isoniazid (INH) | p. 539 |
| Para-Aminosalicyclic Acid | p. 551 |
| Pyrazinamide | p. 559 |
| Antifungal Agents | p. 571 |
| Antifungal Agents: In vitro Susceptibility Testing, Pharmacodynamics, and Prospects for Combination Therapy | p. 573 |
| Amphotericin B | p. 591 |
| Azoles (Clotrimazole, Fluconazole, Itraconazole, Ketoconazole, Miconazole, Voriconazole) | p. 609 |
| Echinocandins (Caspofungin) | p. 637 |
| Flucytosine | p. 651 |
| Nystatin | p. 669 |
| Antiviral Agents | p. 679 |
| Abacavir | p. 681 |
| Adefovir | p. 691 |
| Amantadine, Rimantadine, and Related Agents | p. 705 |
| Cidofovir | p. 731 |
| Enfuvirtide and Other Fusion Inhibitors | p. 747 |
| Ganciclovir | p. 757 |
| Influenza Neuraminidase Inhibitors (Oseltamivir and Zanamivir) | p. 773 |
| Interferons | p. 791 |
| Lamivudine and Emtricitabine | p. 803 |
| Nonnucleoside Analogues (Delavirdine, Efavirenz, Nevirapine) | p. 817 |
| Nucleoside Analogues (Acyclovir, Famciclovir, Penciclovir, Valacyclovir) | p. 835 |
| Nucleoside Analog Reverse Transcriptase Inhibitors (Didanosine, Zalcitabine, Zidovudine) | p. 845 |
| Protease Inhibitors (Amprenavir, Atazanavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir) | p. 865 |
| Ribavirin | p. 909 |
| Stavudine | p. 923 |
| Tenofovir | p. 935 |
| Antiparasitic Agents | p. 947 |
| Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Parasitic Infections | p. 949 |
| 4-Aminoquinolines (Amodiaquine, Chloroquine) | p. 961 |
| Antimonials (Meglumine antimoniate, Sodium stibogluconate) | p. 973 |
| Artemisinin and Its Derivatives | p. 981 |
| Atovaquone and Atovaquone-Proguanil | p. 1003 |
| Benzimidazoles (Albendazole, Mebendazole, Thiabendazole, Triclabendazole) | p. 1021 |
| Benznidazole | p. 1037 |
| Bithionol | p. 1039 |
| Diloxanide Furoate | p. 1041 |
| Eflornithine | p. 1043 |
| Emetine and Dehydroemetine | p. 1047 |
| Folate Antagonists | p. 1049 |
| Furazolidone | p. 1071 |
| Halofantrine | p. 1075 |
| Iodoquinol | p. 1079 |
| Ivermectin | p. 1081 |
| Levamisole | p. 1089 |
| Mefloquine | p. 1091 |
| Melarsoprol | p. 1105 |
| Metrifonate | p. 1109 |
| Niclosamide | p. 1113 |
| Nifurtimox | p. 1115 |
| Nitazoxanide | p. 1117 |
| Oxamniquine | p. 1119 |
| Pentamidine | p. 1123 |
| Piperazine | p. 1127 |
| Piperazine: Diethylcarbamazine | p. 1129 |
| Praziquantel | p. 1135 |
| Primaquine | p. 1145 |
| Pyrantel Pamoate | p. 1161 |
| Pyrvinium Pamoate | p. 1163 |
| Quinacrine | p. 1165 |
| Quinine and Quinidine | p. 1167 |
| Suramin | p. 1195 |
| Table of Contents provided by Rittenhouse. All Rights Reserved. |
